Johnson & Johnson's talc settlement ends one fight. The casualty market's bigger problem remains

The $5.5 billion deal closes out ovarian cancer claims, but the case has become a reference point for an industry still grappling with the cost of American litigation

Commercial risk teams are responding with tighter controls, scenario modeling, and broader collaboration across underwriting, claims, and cyber operations.

Leaders continue to prioritize resilience planning while balancing cost, coverage terms, and operational exposure in a changing market cycle.